Latest Antares Pharma (ATRS) Headlines Antares
Post# of 58
Posted On: 03/12/2014 6:15:51 PM
Latest Antares Pharma (ATRS) Headlines
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men
Business Wire - Thu Feb 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.
Antares Pharma, Inc. [ATRS] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Feb 19, 9:00AM CST
What:
Antares Pharma to Participate in the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 19, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux Jooste, Senior Vice President and General Manager Pharmaceuticals, will participate in the RBC Capital Markets' Global Healthcare Conference on Wednesday February 26, 2014 at 11:00 am Eastern Time.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Business Wire - Wed Jan 15, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of OTREXUP(TM), the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is available at distribution centers throughout the USA.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Is This the Top for Antares Pharma Inc (ATRS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:13AM CST
Is This the Top for Antares Pharma Inc (ATRS)?
Antares Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 11:59AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday January 16, 2014 at 1:00 pm Pacific Time.
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017
M2 - Thu Jan 02, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fj7x3/injectable_drug) has announced the addition of the "2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017" report to their offering. The injectable drug delivery market is technology driven and is marked by the 'Threat of Obsolescence' wherein technologies as well as its adoption by patients changes very rapidly. The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cure serious illnesses but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators. Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Injectable Drug Delivery Devices Technologies Market 5 Global Injectable Drug Delivery Formulation Technologies Market 6 Global Injectable Drug Delivery Technologies Market, By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Alkermes - Antares Pharma - Baxter International - Becton, Dickinson And Company - Bespak Europe - Crossject - Elcam Medical - Eli Lilly And Company - Gerresheimer - Haselmeier - Injex Pharma - Novo Nordisk - Owen Mumford - Sanofi - Schott - Shl Group - Terumo Corporation - Unilife Corporation - Vetter Pharma-Fertigung - West Pharmaceutical Services - Ypsomed Holding - Zogenix For more information visit http://www.researchandmarkets.com/research/5f...table_drug
Antares Pharma(R) Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables
Business Wire - Fri Dec 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. The designs described in the application result in the injector performing the reconstitution of the dry drugs into an injectable liquid form and then perform the injection similar to the Antares VIBEX(R) and QuickShot(TM) devices. Adding the reconstitution mechanism to the base of the VIBEX(R) and QuickShot(TM) injection platform allows the Company to build on its comprehensive technology platform upon which OTREXUP(TM) was developed. The expiry date for the patent issued in August of 2012 is 2028.
Cooperative of American Physicians, Inc. and The Institute for Medical Leadership(R) Offer Chief of Staff Boot Camp(R)
Marketwire - Thu Dec 19, 4:35PM CST
The Cooperative of American Physicians, Inc. (CAP), is a proud sponsor of The Institute for Medical Leadership's Chief of Staff Boot Camp® taking place on January 24-25, 2014 in Santa Monica, CA and on March 21-22, 2014 in New Orleans, LA.
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray
PR Newswire - Thu Dec 19, 7:34AM CST
Editor Note: For more information about this release, please scroll to bottom.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men
Business Wire - Thu Feb 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.
Antares Pharma, Inc. [ATRS] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Feb 19, 9:00AM CST
What:
Antares Pharma to Participate in the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 19, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux Jooste, Senior Vice President and General Manager Pharmaceuticals, will participate in the RBC Capital Markets' Global Healthcare Conference on Wednesday February 26, 2014 at 11:00 am Eastern Time.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Business Wire - Wed Jan 15, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of OTREXUP(TM), the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is available at distribution centers throughout the USA.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Is This the Top for Antares Pharma Inc (ATRS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:13AM CST
Is This the Top for Antares Pharma Inc (ATRS)?
Antares Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 11:59AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday January 16, 2014 at 1:00 pm Pacific Time.
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017
M2 - Thu Jan 02, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fj7x3/injectable_drug) has announced the addition of the "2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017" report to their offering. The injectable drug delivery market is technology driven and is marked by the 'Threat of Obsolescence' wherein technologies as well as its adoption by patients changes very rapidly. The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cure serious illnesses but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators. Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Injectable Drug Delivery Devices Technologies Market 5 Global Injectable Drug Delivery Formulation Technologies Market 6 Global Injectable Drug Delivery Technologies Market, By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Alkermes - Antares Pharma - Baxter International - Becton, Dickinson And Company - Bespak Europe - Crossject - Elcam Medical - Eli Lilly And Company - Gerresheimer - Haselmeier - Injex Pharma - Novo Nordisk - Owen Mumford - Sanofi - Schott - Shl Group - Terumo Corporation - Unilife Corporation - Vetter Pharma-Fertigung - West Pharmaceutical Services - Ypsomed Holding - Zogenix For more information visit http://www.researchandmarkets.com/research/5f...table_drug
Antares Pharma(R) Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables
Business Wire - Fri Dec 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. The designs described in the application result in the injector performing the reconstitution of the dry drugs into an injectable liquid form and then perform the injection similar to the Antares VIBEX(R) and QuickShot(TM) devices. Adding the reconstitution mechanism to the base of the VIBEX(R) and QuickShot(TM) injection platform allows the Company to build on its comprehensive technology platform upon which OTREXUP(TM) was developed. The expiry date for the patent issued in August of 2012 is 2028.
Cooperative of American Physicians, Inc. and The Institute for Medical Leadership(R) Offer Chief of Staff Boot Camp(R)
Marketwire - Thu Dec 19, 4:35PM CST
The Cooperative of American Physicians, Inc. (CAP), is a proud sponsor of The Institute for Medical Leadership's Chief of Staff Boot Camp® taking place on January 24-25, 2014 in Santa Monica, CA and on March 21-22, 2014 in New Orleans, LA.
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray
PR Newswire - Thu Dec 19, 7:34AM CST
Editor Note: For more information about this release, please scroll to bottom.
(0)
(0)Antares Pharma Inc. (ATRS) Stock Research Links
Scroll down for more posts ▼